References
<A NAME="RS03705ST-1">1</A>
New address: 5655 Greenshade Rd, San Diego, CA 92121, USA. Email: sakthi123@earthlink.net.
<A NAME="RS03705ST-2A">2a</A>
Welch T.
Eswarakrishnan S.
Fluorine in Bioorganic Chemistry
Wiley-Interscience;
New York:
1991. and references cited therein
<A NAME="RS03705ST-2B">2b</A>
Mikami K.
Itoh Y.
Yamanaka M.
Chem. Rev.
2004,
104:
1
<A NAME="RS03705ST-3A">3a</A>
Park BK.
Kitteringham NR.
O’Neill PM.
Annu. Rev. Pharmacol. Toxicol.
2001,
41:
443
<A NAME="RS03705ST-3B">3b</A>
Man H.
Corral LG.
Stirrling DI.
Muller GW.
Bioorg. Med. Chem. Lett.
2003,
13:
3415
<A NAME="RS03705ST-4A">4a</A>
FDA-Approved drugs based upon fluorinated nucleosides include 5F-3TC (AIDS) and Gemcitabine(cancer).
<A NAME="RS03705ST-4B">4b</A>
Eldrup AB.
Prhavc M.
Brooks J.
Bhat B.
Prakash TP.
Song Q.
Bera S.
Bhat N.
Dande P.
Cook PD.
Bennet CF.
Carrol SS.
Ball RG.
Bosserman M.
Burlein C.
Colwell LF.
Fay JF.
Flores OA.
Getty K.
LaFamina RL.
Leone J.
MacCoss M.
McMasters DR.
Tomassini JE.
Langen DV.
Wolanski B.
Olseon DB.
J. Med. Chem.
2004,
47:
5284
<A NAME="RS03705ST-4C">4c</A>
Zhou W.
Gumina G.
Chong Y.
Wang J.
Schinazi RF.
Chu CK.
J. Med. Chem.
2004,
47:
3399
<A NAME="RS03705ST-4D">4d</A>
Yang Y.-Y.
Meng W.-D.
Qing F.-L.
Org. Lett.
2004,
6:
4257
<A NAME="RS03705ST-5A">5a</A>
Kool ET.
Acc. Chem. Res.
2002,
35:
936 ; and references cited therein
<A NAME="RS03705ST-5B">5b</A>
Dai Q.
Piccirilli JA.
Org. Lett.
2003,
5:
807
<A NAME="RS03705ST-5C">5c</A>
Lai JS.
Kool ET.
J. Am. Chem. Soc.
2004,
126:
3040
<A NAME="RS03705ST-5D">5d</A>
Robins MJ.
MacCoss M.
Naik SR.
Ramani G.
J. Am. Chem. Soc.
1976,
98:
7381
<A NAME="RS03705ST-5E">5e</A>
Blackburn GM.
Brown D.
Martin SJ.
Parratt MJ.
J. Chem. Soc., Perkin Trans. 1
1987,
181
<A NAME="RS03705ST-6">6</A>
Kawasaki AM.
Casper MD.
Freier SM.
Lesnik EA.
Zounes MC.
Cummins LL.
Gonzalez C.
Cook PD.
J. Med. Chem.
1993,
36:
831
<A NAME="RS03705ST-7A">7a</A>
Layzer JM.
Mccaffrey AP.
Tanner AK.
Huang Z.
Kay MA.
Sullenger BA.
RNA
2004,
10:
766
<A NAME="RS03705ST-7B">7b</A>
Allerson CR.
Sioufi N.
Jarres R.
Prakash TP.
Naik N.
Berdeja A.
Wanders L.
Griffey RH.
Swayze EE.
Bhat B.
J. Med. Chem.
2005,
48:
901
<A NAME="RS03705ST-8A">8a</A>
Cook PD.
Allen LB.
Streeter DG.
Huffman JH.
Sidwell RW.
Robins RK.
J. Med. Chem.
1978,
21:
1212
<A NAME="RS03705ST-8B">8b</A>
Allen LB.
Huffman JH.
Cook PD.
Meyer RB.
Robins RK.
Sidwell RW.
Antimicrob. Agents Chemother.
1977,
12:
114
<A NAME="RS03705ST-8C">8c</A>
Saunder PP.
Chao LY.
Loo TL.
Robins RK.
Biochem. Pharmacol.
1981,
30:
2374
<A NAME="RS03705ST-8D">8d</A>
Revangar GR.
Gupta PK.
Adams AD.
Dalley NK.
McKernana PA.
Cook PD.
Canonico PG.
Robins RK.
J. Med. Chem.
1984,
27:
1389
<A NAME="RS03705ST-9">9</A>
Kumar A.
Khan SI.
Manglani A.
Khan ZK.
Katti SB.
Nucleosides Nucleotides
1994,
13:
1049 ; and references cited therein
<A NAME="RS03705ST-10A">10a</A>
Eldrup AB.
Allerson CR.
Bennet CF.
Bera S.
Bhat B.
Bosserman M.
Brooks J.
Burlein C.
Carrol SS.
Cook PD.
Getty KL.
MacCoss M.
McMasters DR.
Olseon DB.
Prakash TP.
Prhavc M.
Song Q.
Tomassini JE.
Xia J.
J. Med. Chem.
2004,
47:
2283
<A NAME="RS03705ST-10B">10b</A>
Shim J.
Larson G.
Lai V.
Naim S.
Wu JZ.
Antiviral Res.
2003,
58:
243
<A NAME="RS03705ST-10C">10c</A>
Ismaili H,
Moulay A,
Cheng Y,
Lavalle J,
Siddiqui A, and
Storrer R. inventors; Intl. Patent. Appl. WO 01/60315.
<A NAME="RS03705ST-10D">10d</A>
Sommadossi JP, and
Lacolla P. inventors; Intl. Patent Appl. WO 01/92282.
<A NAME="RS03705ST-11">11</A>
Minakawa N.
Kojima N.
Matsuda A.
J. Org. Chem.
1999,
64:
7158
<A NAME="RS03705ST-12">12</A> However, synthesis and biological properties of 2,3-difluoro-3-deaza-Ad, 3-F-3-deaza-Ad,
3-Br-3-deaza-G and 3-Cl-3-deaza-G were reported. See:
Liu MC.
Luo MZ.
Mozdziesz DE.
Lin TS.
Dutschman GE.
Gullen EA.
Cheng YC.
Sartorelli AC.
Nucleosides, Nucleotides Nucleic Acids
2001,
20:
1975
<A NAME="RS03705ST-13">13</A>
Minakawa N.
Sasabuchi Y.
Kiyosue A.
Kojima N.
Matsuda A.
Chem. Pharm. Bull.
1996,
44:
288
<A NAME="RS03705ST-14">14</A>
Robins RK.
Horner JK.
Greco CV.
Noell CW.
Beames CG.
J. Org. Chem.
1963,
28:
3041
<A NAME="RS03705ST-15A">15a</A>
Cook PD.
Rousseau RJ.
Mian AM.
Meyer RB.
Dea P.
Ivanovics G.
Streeter DG.
Witkowski JT.
Stout MG.
Simon LN.
Sidwell RW.
Robins RK.
J. Am. Chem. Soc.
1975,
97:
2916
<A NAME="RS03705ST-15B">15b</A>
Carrol SS,
LaFemina RL,
Hall DL,
Himmelberger AL,
Kuo LC,
MacCoss M,
Olseon DB,
Rutkowski CA,
Tomassini JE,
An H,
Bhat B,
Bhat N,
Cook PD,
Eldrup AB,
Guinosso CJ,
Prhavc M, and
Prakash TP. inventors; Intl. Patent. Appl. WO 02/057425.
<A NAME="RS03705ST-16A">16a</A>
Harry-O’kuru RE.
Smith JM.
Wolfe MS.
J. Org. Chem.
1997,
62:
1754
<A NAME="RS03705ST-16B">16b</A>
Franchetti P.
Cappellacci L.
Marchetti S.
Trincavelli L.
Martini C.
Mazzoni MR.
Lucacchini A.
Grifantini M.
J. Med. Chem.
1998,
41:
1708
<A NAME="RS03705ST-17">17</A>
Niedballa U.
Vorbrüggen HJ.
J. Org. Chem.
1974,
39:
3654
<A NAME="RS03705ST-18">18</A>
Acevedo OL.
Andrews RS.
Cook PD.
Nucleosides Nucleotides
1993,
12:
403
<A NAME="RS03705ST-19">19</A>
Compound 5a (diastereomers 1:1): 1H NMR (300 MHz, CDCl3): δ = 3.92 (s, 3 H, OCH3), 4.66-4.90 (m, 3 H, 4′, 5′,5′′-H), 5.90-6.06 (m, 2 H, 2′,3′-H), 6.48 (d, J = 6.7 Hz, 1 H, 1′-H), 7.31-7.63 (m, 10 H, 9 Ar-H, Imi-2-H), 7.92-8.14 (m, 7 H, 6
× Ar-H, CHFCN). 19F NMR (282 MHz, CDCl3): δ (diastreomers) = -175.76 (d, J
F-H = 43.6 Hz), -172.72 (d, J
F-H = 43.6 Hz). HRMS: m/z calcd for C33H26FN3O9 [MNa+]: 650.1551; found: 650.1550. ESI-MS: m/z = 650 [MNa+].
Compound 5b (diastereomers 1:1): 1H NMR (300 MHz, CDCl3): δ = 2.15 (s, 3 H, COCH3), 2.20-2.50 (m, 5 H, 3′,3′′-H, Tol-CH3), 3.94 (s, 3 H, OCH3), 4.53-4.75 (m, 3 H, 4′, 5′,5′′-H), 5.40-5.46 (m, 1 H, 2′-H), 6.13-6.16 (m, 1 H,
1′-H), 7.25 (m, 2 H, Ar-H), 7.41 (d, 1 H, J = 43.1 Hz, CHFCN), 7.86-7.98 (m, 3 H, 2 × Ar-H, Imi-2-H). 19F NMR (282 MHz, CDCl3): δ (diastreomers) = -176.41 (d, J
F-H = 43.6 Hz),
-174.03 (d, J
F-H = 43.6 Hz). HRMS: m/z calcd for C22H22FN3O7 [MNa+]: 482.1334; found: 482.1333. ESI-MS: m/z = 482 [MNa+].
Compound 5c (diastereomers 1:1): 1H NMR (300 MHz, CDCl3): δ = 1.58 (2 × s, 3 H, CH3), 3.98 (2 × s, 3 H, OCH3), 4.78-4.96 (m, 3 H, 4′, 5′,5′′-H), 5.75 (2 × d, 1 H, 3′-H), 6.66 and 6.80 (2 × s,
1 H, 1′-H), 7.26-7.62 (m, 10 H, 9 × Ar-H, Imi-2-H), 7.80-8.19 and 8.20 (m, 7 H, 6
× Ar-H, CHFCN). 19F NMR (282 MHz, CDCl3): δ (diastereomers) = -179.31 (d, J
F-H = 41.6 Hz), -170.0 (d, J
F-H = 41.6 Hz). HRMS: m/z calcd for C34H28FN3O9 [MNa+]: 664.1707; found: 664.1704. ESI-MS: m/z = 664 [MNa+].
<A NAME="RS03705ST-20A">20a</A>
Cook PD.
Rousseau RJ.
Mian AM.
Dea P.
Meyar RB.
Robins RK.
J. Am. Chem. Soc.
1976,
98:
1492
<A NAME="RS03705ST-20B">20b</A>
Tanaka H.
Hirayama M.
Suzuki M.
Miyasaka T.
Matsuda A.
Ueda T.
Tetrahedron
1986,
42:
1971
<A NAME="RS03705ST-21A">21a</A>
Cook PD.
Robins RK.
J. Org. Chem.
1978,
43:
289
<A NAME="RS03705ST-21B">21b</A>
Revankar GR.
Gupta PK.
Adams AD.
Dalley NK.
McKernana PA.
Cook PD.
Canonico PG.
Robins RK.
J. Med. Chem.
1984,
27:
1389
<A NAME="RS03705ST-22">22</A>
Compound 12a (diastereomers 1:3): 1H NMR (300 MHz, DMSO-d
6): δ = 3.45-3.70 (m, 5 H, 2′, 3′-H, OCH3), 3.85-3.86 (m, 1 H, 4′-H), 4.04-4.16 (m, 2 H, 5′,5′′-H), 5.08-5.22 (m, 2 H, 3′,
5′′-OH), 5.40 and 5.49 (2 × d, J = 4.1, 4.7 Hz, 1 H, 2′-OH), 5.51 (d, J = 5.56 Hz, 1 H, 1′-H), 7.17 (d, J
H-F = 44.8 Hz, 0.3 H, CHF), 7.22 (d, J
H-F = 44.8 Hz, 0.7 H, CHF), 7.40 and 7.60 (2 × br s, 2 H, NH2), 8.21 and 8.24 (2 × br s, 1 H, Imi-2H), 8.50 (br s, 1 H, NH). 19F NMR (282 MHz, CDCl3): δ (diastereomers) = -176.84 (d, J
F-H = 43.6 Hz),
-173.84 (d, J
F-H = 43.6 Hz). HRMS: m/z calcd for C12H17FN4O6 [MNa+] = 355.1030; found: 355.1034. ESI-MS: m/z = 355 [MNa+].
<A NAME="RS03705ST-23">23</A>
To our surprise, 5-imidomethoxy imidazole-4-carboxamide riboside analogues similar
to 12a have never been detected, or proposed to form, during the cyclization reactions of
4a or 10a in basic alcoholic solutions. See ref. 11 and ref. 20.
<A NAME="RS03705ST-24">24</A>
A similar ring-closure was also effected successfully when using 5% Na2CO3 in EtOH, but, because of its high polarity, we had difficulties in isolating the
product from the inorganic salt. Although the ring-closure reaction could also be
realized using several organic amine bases (DBU, pyridine, N,N-diisopropylethylamine, etc.), we prefer to use less volatile Et3N base.
<A NAME="RS03705ST-25">25</A>
Although the conversions of the ring-closure reactions were >80%, the high polarities
of products 3a-c restricted their isolated yields to only 60-68%.
<A NAME="RS03705ST-26">26</A>
Compound 3b: UV (0.5 N NaOH): λmax = 287 nm (ε 9400). 1H NMR (300 MHz, DMSO-d
6): δ = 1.80-1.88 (m, 1 H, 3′-H), 2.08-2.18 (m, 1 H, 3′′-H), 3.51-3.55 (m, 1 H, 5′-H),
3.64-3.67 (m, 1 H, 5′′-H), 4.28-4.42 (m, 2 H, 4′-H, 2′-OH), 5.01 (t, 1 H, J = 5.3 Hz, 5′-OH), 5.52 (br s, 2 H, NH2), 5.61 (d, J = 4.4 Hz, 1 H, 2′-H), 5.78 (s, 1 H, 1′-H), 8.04 (s, 1 H, 2-H), 10.44 (br s, 1 H,
NH). 19F NMR (282 MHz, DMSO-d
6): δ = -186.70. 13C NMR (75 MHz, DMSO-d
6): δ = 34.6, 62.9, 76.4, 81.7, 93.1 (d, J = 5.5 Hz), 122.2 (d, J = 215.0 Hz), 123.2, 132.1 (d, J = 9.0 Hz), 135.9 (d, J = 22.0 Hz), 137.6, 155.0. HRMS: m/z calcd for C11H14FN4O4 [MH+] = 285.0999; found: 285.0991; [MNa+]: 307.0819; found: 307.0809. ESI-MS: m/z = 285 [MH+].
Compound 3c: UV (H2O): λmax = 272 nm (ε 8200), 310 nm (ε 7100). 1H NMR (300 MHz, DMSO-d
6): δ = 0.71 (s, 3 H, CH3), 3.62-3.69 (m, 1 H, 5′-H), 3.82-3.93 (m, 3 H, 3′,4′,5′′-H), 5.15 (s, 1 H, 2′-OH),
5.21-5.27 (m, 2 H, 3′,5′-OH), 5.54 (br s, 2 H, NH2), 5.77 (s, 1 H, 1′-H), 8.24 (s, 1 H, 2-H), 10.46 (br s, 1 H, NH). 19F NMR (282 MHz, DMSO-d
6): δ =
-186.46. 13C NMR (75 MHz, DMSO-d
6): δ = 20.5, 59.7, 71.7, 79.5, 83.0, 93.3 (d, J = 7 Hz), 122.2 (d, J = 214 Hz), 122.9, 132.2 (d, J = 9 Hz), 135.9 (d, J = 22 Hz), 137.5, 155.0. HRMS: m/z calcd for C12H16FN4O5 [MH+]: 315.1105; found: 315.1102; [MNa+]: 337.0924; found: 337.0920. ESI-MS: m/z = 315 [MH+].